168 related articles for article (PubMed ID: 20153190)
21. Dimeric C34 Derivatives Linked through Disulfide Bridges as New HIV-1 Fusion Inhibitors.
Kobayakawa T; Ebihara K; Honda Y; Fujino M; Nomura W; Yamamoto N; Murakami T; Tamamura H
Chembiochem; 2019 Aug; 20(16):2101-2108. PubMed ID: 31012222
[TBL] [Abstract][Full Text] [Related]
22. Design, synthesis, and biological evaluation of N-carboxyphenylpyrrole derivatives as potent HIV fusion inhibitors targeting gp41.
Liu K; Lu H; Hou L; Qi Z; Teixeira C; Barbault F; Fan BT; Liu S; Jiang S; Xie L
J Med Chem; 2008 Dec; 51(24):7843-54. PubMed ID: 19053778
[TBL] [Abstract][Full Text] [Related]
23. [The current progress in the development of HIV-1 fusion inhibitors].
Shi WG; Jia QY; Liu KL
Yao Xue Xue Bao; 2010 Feb; 45(2):184-93. PubMed ID: 21351428
[TBL] [Abstract][Full Text] [Related]
24. Design, synthesis, and biological activity of novel 5-((arylfuran/1H-pyrrol-2-yl)methylene)-2-thioxo-3-(3-(trifluoromethyl)phenyl)thiazolidin-4-ones as HIV-1 fusion inhibitors targeting gp41.
Jiang S; Tala SR; Lu H; Abo-Dya NE; Avan I; Gyanda K; Lu L; Katritzky AR; Debnath AK
J Med Chem; 2011 Jan; 54(2):572-9. PubMed ID: 21190369
[TBL] [Abstract][Full Text] [Related]
25. Development of HIV-1 fusion inhibitors targeting gp41.
Lu K; Asyifah MR; Shao F; Zhang D
Curr Med Chem; 2014 Jun; 21(17):1976-96. PubMed ID: 24350848
[TBL] [Abstract][Full Text] [Related]
26. An amphiphilic conjugate approach toward the design and synthesis of betulinic acid-polyphenol conjugates as inhibitors of the HIV-1 gp41 fusion core formation.
Liu Y; Ke Z; Wu KY; Liu S; Chen WH; Jiang S; Jiang ZH
ChemMedChem; 2011 Sep; 6(9):1654-64. PubMed ID: 21688394
[TBL] [Abstract][Full Text] [Related]
27. Footprint-based identification of viral entry inhibitors targeting HIVgp41.
Holden PM; Kaur H; Goyal R; Gochin M; Rizzo RC
Bioorg Med Chem Lett; 2012 Apr; 22(8):3011-6. PubMed ID: 22425565
[TBL] [Abstract][Full Text] [Related]
28. Design, synthesis and biological evaluation of novel 5-((substituted quinolin-3-yl/1-naphthyl) methylene)-3-substituted imidazolidin-2,4-dione as HIV-1 fusion inhibitors.
Ibrahim TS; Bokhtia RM; Al-Mahmoudy AMM; Taher ES; AlAwadh MA; Elagawany M; Abdel-Aal EH; Panda S; Gouda AM; Asfour HZ; Alhakamy NA; Youssif BGM
Bioorg Chem; 2020 Jun; 99():103782. PubMed ID: 32229348
[TBL] [Abstract][Full Text] [Related]
29. Discovery of HIV fusion inhibitors targeting gp41 using a comprehensive α-helix mimetic library.
Whitby LR; Boyle KE; Cai L; Yu X; Gochin M; Boger DL
Bioorg Med Chem Lett; 2012 Apr; 22(8):2861-5. PubMed ID: 22424973
[TBL] [Abstract][Full Text] [Related]
30. Covalent fusion inhibitors targeting HIV-1 gp41 deep pocket.
Bai Y; Xue H; Wang K; Cai L; Qiu J; Bi S; Lai L; Cheng M; Liu S; Liu K
Amino Acids; 2013 Feb; 44(2):701-13. PubMed ID: 22961335
[TBL] [Abstract][Full Text] [Related]
31. Conformational flexibility of the conserved hydrophobic pocket of HIV-1 gp41. Implications for the discovery of small-molecule fusion inhibitors.
Cano-Muñoz M; Jurado S; Morel B; Conejero-Lara F
Int J Biol Macromol; 2021 Dec; 192():90-99. PubMed ID: 34619276
[TBL] [Abstract][Full Text] [Related]
32. N-substituted pyrrole derivatives as novel human immunodeficiency virus type 1 entry inhibitors that interfere with the gp41 six-helix bundle formation and block virus fusion.
Jiang S; Lu H; Liu S; Zhao Q; He Y; Debnath AK
Antimicrob Agents Chemother; 2004 Nov; 48(11):4349-59. PubMed ID: 15504864
[TBL] [Abstract][Full Text] [Related]
33. Enhanced potency of bivalent small molecule gp41 inhibitors.
Sofiyev V; Kaur H; Snyder BA; Hogan PA; Ptak RG; Hwang P; Gochin M
Bioorg Med Chem; 2017 Jan; 25(1):408-420. PubMed ID: 27908751
[TBL] [Abstract][Full Text] [Related]
34. Approaches for identification of HIV-1 entry inhibitors targeting gp41 pocket.
Yu F; Lu L; Du L; Zhu X; Debnath AK; Jiang S
Viruses; 2013 Jan; 5(1):127-49. PubMed ID: 23344560
[TBL] [Abstract][Full Text] [Related]
35. Recent Progress in the Development of HIV-1 Entry Inhibitors: From Small Molecules to Potent Anti-HIV Agents.
Suttisintong K; Kaewchangwat N; Thanayupong E; Nerungsi C; Srikun O; Pungpo P
Curr Top Med Chem; 2019; 19(18):1599-1620. PubMed ID: 31424370
[TBL] [Abstract][Full Text] [Related]
36. Identification of a human protein-derived HIV-1 fusion inhibitor targeting the gp41 fusion core structure.
Chao L; Lu L; Yang H; Zhu Y; Li Y; Wang Q; Yu X; Jiang S; Chen YH
PLoS One; 2013; 8(5):e66156. PubMed ID: 23741527
[TBL] [Abstract][Full Text] [Related]
37. Revisiting the mechanism of enfuvirtide and designing an analog with improved fusion inhibitory activity by targeting triple sites in gp41.
Xu W; Pu J; Su S; Hua C; Su X; Wang Q; Jiang S; Lu L
AIDS; 2019 Aug; 33(10):1545-1555. PubMed ID: 30932963
[TBL] [Abstract][Full Text] [Related]
38. HIV-1 gp41 fusion intermediate: a target for HIV therapeutics.
Pan C; Liu S; Jiang S
J Formos Med Assoc; 2010 Feb; 109(2):94-105. PubMed ID: 20206833
[TBL] [Abstract][Full Text] [Related]
39. Design, synthesis and biological evaluation of 3-substituted 2,5-dimethyl-N-(3-(1H-tetrazol-5-yl)phenyl)pyrroles as novel potential HIV-1 gp41 inhibitors.
He XY; Zou P; Qiu J; Hou L; Jiang S; Liu S; Xie L
Bioorg Med Chem; 2011 Nov; 19(22):6726-34. PubMed ID: 22014749
[TBL] [Abstract][Full Text] [Related]
40. A Helical Short-Peptide Fusion Inhibitor with Highly Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus.
Xiong S; Borrego P; Ding X; Zhu Y; Martins A; Chong H; Taveira N; He Y
J Virol; 2017 Jan; 91(1):. PubMed ID: 27795437
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
